search
Back to results

A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements

Primary Purpose

Healthy

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Single-arm
Sponsored by
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Healthy focused on measuring whole blood clotting time

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Signed and dated, written informed consent (Institutional Review Board [IRB]-approved informed consent form [ICF]).
  2. Healthy male and female subjects aged 18 to 65 years (inclusive) with suitable veins for venipuncture. (Healthy as determined by medical history)

Exclusion Criteria:

  1. Healthy subjects who do not conform to the above inclusion criteria.
  2. Healthy subjects who cannot communicate reliably with the Investigator.
  3. History of major bleeding or major trauma within the past 6 months
  4. Healthy volunteer with a propensity to bleed (i.e. due to recent trauma, recent surgery, peptic ulcer, active or recent gastrointestinal bleeding or bleeding from hemorrhoids).
  5. Significant infection or known inflammatory process within 2 weeks of screening.
  6. Treatment with any investigational products or therapies within 30 days (or 5 half lives, whichever is greater) prior to screening.
  7. Received non-steroidal anti-inflammatory (NSAID) or medications (including any type of anticoagulant or aspirin [ASA]) with a direct effect on hemostasis within 7 days of testing
  8. Unwillingness or inability to comply with procedures required in this protocol.
  9. Subjects who are concurrently enrolled in any other clinical study.

Sites / Locations

  • Quintiles Phase I Services, LLC

Arms of the Study

Arm 1

Arm Type

No Intervention

Arm Label

Single-arm

Arm Description

healthy volunteers

Outcomes

Primary Outcome Measures

Variability in whole blood clotting time measurement
Assessment of variability in whole blood clotting time measurements in human blood collected from volunteers in across five technicians

Secondary Outcome Measures

Full Information

First Posted
July 28, 2014
Last Updated
May 19, 2020
Sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Collaborators
Quintiles, Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02205827
Brief Title
A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements
Official Title
A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements
Study Type
Interventional

2. Study Status

Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
April 2014 (undefined)
Primary Completion Date
May 2014 (Actual)
Study Completion Date
May 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Collaborators
Quintiles, Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of the study is to characterize the distribution and sources of variability in whole blood clotting time (WBCT) measurements in human blood collected from healthy volunteers by 5 different technicians.
Detailed Description
No investigational product was administered to any subject in this study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Healthy
Keywords
whole blood clotting time

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Single-arm
Arm Type
No Intervention
Arm Description
healthy volunteers
Intervention Type
Other
Intervention Name(s)
Single-arm
Other Intervention Name(s)
Whole Blood Clotting Time assessment
Intervention Description
collection of blood for assessment of whole blood clotting time
Primary Outcome Measure Information:
Title
Variability in whole blood clotting time measurement
Description
Assessment of variability in whole blood clotting time measurements in human blood collected from volunteers in across five technicians
Time Frame
1 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Signed and dated, written informed consent (Institutional Review Board [IRB]-approved informed consent form [ICF]). Healthy male and female subjects aged 18 to 65 years (inclusive) with suitable veins for venipuncture. (Healthy as determined by medical history) Exclusion Criteria: Healthy subjects who do not conform to the above inclusion criteria. Healthy subjects who cannot communicate reliably with the Investigator. History of major bleeding or major trauma within the past 6 months Healthy volunteer with a propensity to bleed (i.e. due to recent trauma, recent surgery, peptic ulcer, active or recent gastrointestinal bleeding or bleeding from hemorrhoids). Significant infection or known inflammatory process within 2 weeks of screening. Treatment with any investigational products or therapies within 30 days (or 5 half lives, whichever is greater) prior to screening. Received non-steroidal anti-inflammatory (NSAID) or medications (including any type of anticoagulant or aspirin [ASA]) with a direct effect on hemostasis within 7 days of testing Unwillingness or inability to comply with procedures required in this protocol. Subjects who are concurrently enrolled in any other clinical study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
James Costin, MD
Organizational Affiliation
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Official's Role
Study Director
Facility Information:
Facility Name
Quintiles Phase I Services, LLC
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66211
Country
United States

12. IPD Sharing Statement

Learn more about this trial

A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements

We'll reach out to this number within 24 hrs